Sign in
ANL Stock Price, Chart, Stats & News
Adlai Nortye Ltd.
Save
Adlai Nortye Ltd. (ANL) does not currently pay a dividend.
824.33M
Market cap
–
Current P/E
–
Forward P/E
ANL chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -72.81% |
ROE | -98.95% |
D/E | 1.07x |
Interest coverage ratio | -28.22x |
ANL valuation
P/E | – |
P/S | – |
P/B | 2.70x |
P/CF | -1.33x |
P/FCF | -3.88x |
P/OCF | -1.33x |
PEG | -0.01x |
EV multiple | -4.90x |
About
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas.
Similar securities
Based on sector and market capitalization
Report issue